Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

India’s Piramal Pharma Rings The Bell On Domestic Stock Exchange Listings

Newly Independent Firm Has $250m Revenue Complex Generic Hospital Unit

Executive Summary

Piramal Pharma is “embarking on a new journey as a focused pharma entity,” as it seeks to “identify and secure inorganic and organic growth opportunities to generate consistent shareholder value.”

You may also be interested in...



Who’s Hired? O’Brien To Replace Richards As Mayne Pharma CEO

Mayne Pharma has announced the appointment of pharma industry veteran Shawn O’Brien as CEO, replacing outgoing delegate Scott Richards. Plus, Hikma has appointed two new female board members, in line with gender diversity targets set by the UK Financial Conduct Authority.

Piramal Invests Almost $75m In Expanding Manufacturing Capacity

Piramal Pharma’s Piramal Pharma Solutions contract development and manufacturing organization has invested around $75m in expanding its antibody-drug conjugate capabilities at its Grangemouth facility in Scotland and investing in a new active pharmaceutical ingredient infrastructure at the Morpeth facility in England.

Abbott acquires Piramal's domestic formulations business for $3.7 billion

Abbott has signed a definitive agreement to acquire Piramal Healthcare's domestic formulations business for an up-front payment of $2.12 billion and additional annual payments of $400 million for the next four years starting in 2011.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152237

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel